European Psychiatry - Volume 41 - April 2017

825 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846 S821
Results Predictors of high efficiency of amisulpride therapy were
identified: clinical–total score according to PANSS less than 70, sum
of scores according to subscale of negative disorders is more than
31 and immunological–number of HLADR ±lymphocytes below
0.34 ×109/L, CD16 ±lymphocytes more than 0.18 ×109/L.
Conclusion Complex of informative clinical-immunological crite-
ria is proposed, which enables prognosis of the efficiency of
psychopharmacotherapy for patients at admission. It enables opti-
mizing the choice of differentiated therapeutic tactics and height-
ening the quality of specialized medical care for schizophrenic
patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1270
Can writing be used to study and
improve the socio-cognitive
functioning of individuals diagnosed
with schizophrenia?
L. Lucic ∗, A. Khan , C. Daiute
1 Pratt Institute, Social Science and Cultural Studies, New York, USA
2 The Nathan S. Kline Institute for Psychiatric Research, Manhattan
Psychiatric Center, New York, USA
3 The Graduate Center of CUNY, Psychology, New York, USA
∗ Corresponding author.
Impairments in social and cognitive functioning are some of
the most disabling features of the schizophrenia. They result
in poorer communication with others, difficulties in maintain-
ing employment status and decrease in community involvement.
Recently, cognitive remediation therapy (CRT), which relies on
computer-based drill and practice exercises, has emerged as a
nonpharmacological intervention that aims to target and improve
cognitive and social functions. Given the recent success of CRT
based approaches, the question arises: can other nonpharma-
cological interventions which aim to augment and improve
socio-cognitive functions be effective? Building upon Vygot-
sky’s (1934) theorizing, we conducted an 8-week long study
involving 19 participants. The study uses the methodology of
narrative inquiry to examine participants’ ability to employ var-
ied socio-cognitive functions (affect, causation, perceptive-taking,
logical/hypothetical inference, etc.) when writing about every-
day activities and attempting to resolve conflicts in narratives.
Prompts employed in this study directed participants to write
about three different socio-cultural contexts: (1) inpatient; (2) out-
patient and (3) a fictional context. The fictional context aimed
to examine participant’s ability to imagine and express alterna-
tive futures/scenarios. Data show significantly higher frequency
of occurrence of linguistic devices tied to cognitive functions
in (3) fictional narrative context when compared to either (1)
inpatient or (2) outpatient context. Use of affect was the only
statistically significant difference between contexts (1) and (2).
Findings indicate that individuals diagnosed with schizophre-
nia are able to vary the use of social and cognitive functions
across narrative contexts, suggesting that future socio-cognitive
interventions can be anchored in mindfully planned narrative
activities.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1271
Antipsychotic polypharmacy among
schizophrenia outpatients
H. Maatallah∗, H. Ben Ammar , A. Aissa , R. Nefzi , M. Said ,
Z. El Hechmi
Razi Hospital, Psy F, Tunis, Tunisia
∗ Corresponding author.
Introduction Since their introduction by Delay and Deniker in the
1950s, neuroleptic drugs have significantlymodified the evolution-
ary prognosis of schizophrenia. Their combination has also become
a widespread practice.
Objectives The aim of this study was to analyze the associations
of neuroleptic drugs by describing the characteristics of types and
doses, understanding the reasons for these associations and study-
ing the relationship existing in such situation regarding adherence
to treatment, tolerance and the number of hospitalizations.
Methods Our study was retrospective, descriptive and analyt-
ical. It has been conducted from March, 1st to May, 30th 2015
and involved 70 stabilized patients diagnosed with schizophrenia
according to DSM 5. Clinical characteristics were collected from
patients and their medical records. Evaluations were conducted
using PANSS, MARS and GAS.
Results Overall, 70 male patients were recruited. The mean age
was 40 years old: 30% received classical monotherapy while 70%
were treated only by an atypical antipsychotic. Among patients
receiving two drugs, 85% received classical bitherapywhile 9%were
under both classical and atypical drugs. Only 6% received atypical
bitherapy. Chlorpromazine equivalent doses in case of monother-
apy was 325.92mg/day, while it reached 1148.65mg/day in case of
drugs association. Administration of a combined therapy had poor
tolerance rate and all patients suffered fromadverse effects. Adher-
ence to treatment was better while receiving monotherapy (88%
versus 45%) and the number of hospitalizations was lower with an
average of 3 against 10.
Conclusion Our study revealed several shortcomings in our cur-
rentmanagement of patientswith schizophrenia and addressed the
implication of socioeconomic status on therapeutic outcomes.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1272
Human induced pluripotent stem cells
(hiPSCs) in schizophrenia: Modelling
the disease and the treatment
response
M. Marcatili ∗, F. Marsoner , A. D’Agostino , S. Scarone ,
L. Conti
1 University of Milan, Department of Health Sciences, Milano, Italy
2 University of Trento, Center for Integrative Biology - CIBIO-
Laboratory of Stem Cell Biology, Trento, Italy
∗ Corresponding author.
Response to drug treatment is under the sophisticated control
of complex signalling pathways and gene regulatory networks.
Indeed, drug-induced modulation of dysregulated gene expression
and altered synaptic plasticity are critical steps for the successful
treatment of neuropsychiatric disorders. Among the antipsychotic
drugs, clozapine (CLZ) is widely considered to be the most effec-
tive medication for the treatment of schizophrenia. However, due
to its high risk for severe side effects, CLZ use is currently restricted
to patients who do not respond to other antipsychotics. Nonethe-
less, up to 20% of patients are considered nonresponders to CLZ
treatment. The mechanism of action underlying CLZ’s exceptional
clinical efficacy in SCZ is not fully understood. In this context,
in vitro molecular and functional assessment of patient-derived
glutamatergic andGABAergic neurons’ properties aremandatory to
reveal the mechanisms underlying CLZ responsiveness and might
mirror the clinical response. Here, we will describe the genera-
tion of hiPSCs from SCZ patients, classified based on their response
to conventional treatments, to CLZ or total resistance to every
treatment. These patient-specific hiPSCs have been converted into